Olema appoints Jason O'Byrne as CFO ahead of pivotal OPERA-01 data readout

Filed August 13, 2026 · Period ending August 13, 2026 · ~1 min read

Key Changes

• high

  Jason O'Byrne appointed CFO effective August 11, 2026, bringing two decades of biotech finance experience including CFO roles at Vir Biotechnology and Caribou Biosciences (where he led the IPO).

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• high

  Appointment comes as Olema approaches pivotal OPERA-01 trial data and prepares for its first potential commercial launch, signaling entry into a critical development and commercialization phase.

  Exhibit 99.1 view on EDGAR →
• medium

  O'Byrne receives $545K base salary, 45% target bonus (~$245K), $350K sign-on bonus (paid over two years), and 650K stock option grant vesting over four years with one-year cliff.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →